# A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

> **NCT05077449** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** XZP-3287+Fulvestrant
- **DRUG:** Placebo + Fulvestrant

## Key facts

- **NCT ID:** NCT05077449
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-16
- **Primary completion:** 2024-02-22
- **Final completion:** 2029-11
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077449, "A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05077449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*